These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 27406745)

  • 1. Decreased NK-cell tumour immunosurveillance consequent to JAK inhibition enhances metastasis in breast cancer models.
    Bottos A; Gotthardt D; Gill JW; Gattelli A; Frei A; Tzankov A; Sexl V; Wodnar-Filipowicz A; Hynes NE
    Nat Commun; 2016 Jul; 7():12258. PubMed ID: 27406745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the JAK/STAT Signaling Pathway for Breast Cancer.
    Shao F; Pang X; Baeg GH
    Curr Med Chem; 2021; 28(25):5137-5151. PubMed ID: 33290193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Network pharmacology of JAK inhibitors.
    Moodley D; Yoshida H; Mostafavi S; Asinovski N; Ortiz-Lopez A; Symanowicz P; Telliez JB; Hegen M; Clark JD; Mathis D; Benoist C
    Proc Natl Acad Sci U S A; 2016 Aug; 113(35):9852-7. PubMed ID: 27516546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. JAK Inhibition Differentially Affects NK Cell and ILC1 Homeostasis.
    Vian L; Le MT; Gazaniga N; Kieltyka J; Liu C; Pietropaolo G; Dell'Orso S; Brooks SR; Furumoto Y; Thomas CJ; O'Shea JJ; Sciumè G; Gadina M
    Front Immunol; 2019; 10():2972. PubMed ID: 31921209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the NF-κB pathway enhances responsiveness of mammary tumors to JAK inhibitors.
    Bapat AS; O'Connor CH; Schwertfeger KL
    Sci Rep; 2023 Apr; 13(1):5349. PubMed ID: 37005447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. JAK inhibitors alter NK cell functions and may impair immunosurveillance against lymphomagenesis.
    Nocturne G; Pascaud J; Ly B; Tahmasebi F; Mariette X
    Cell Mol Immunol; 2020 May; 17(5):552-553. PubMed ID: 31664224
    [No Abstract]   [Full Text] [Related]  

  • 7. The human ortholog of granulocyte macrophage colony-stimulating factor and interleukin-2 fusion protein induces potent ex vivo natural killer cell activation and maturation.
    Penafuerte C; Bautista-Lopez N; Boulassel MR; Routy JP; Galipeau J
    Cancer Res; 2009 Dec; 69(23):9020-8. PubMed ID: 19920194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of ADAM10 and ADAM17 Inhibitors on Natural Killer Cell Expansion and Antibody-dependent Cellular Cytotoxicity Against Breast Cancer Cells
    Pham DH; Kim JS; Kim SK; Shin DJ; Uong NT; Hyun H; Yoon MS; Kang SJ; Ryu YJ; Cho JS; Yoon JH; Lee JS; Cho D; Lee SH; Park MH
    Anticancer Res; 2017 Oct; 37(10):5507-5513. PubMed ID: 28982863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IL-2- or IL-15-activated NK cells enhance Cetuximab-mediated activity against triple-negative breast cancer in xenografts and in breast cancer patients.
    Roberti MP; Rocca YS; Amat M; Pampena MB; Loza J; Coló F; Fabiano V; Loza CM; Arriaga JM; Bianchini M; Barrio MM; Bravo AI; Domenichini E; Chacón R; Mordoh J; Levy EM
    Breast Cancer Res Treat; 2012 Dec; 136(3):659-71. PubMed ID: 23065032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. JAK/STAT proteins and their biological impact on NK cell development and function.
    Vargas-Hernández A; Forbes LR
    Mol Immunol; 2019 Nov; 115():21-30. PubMed ID: 30704805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of decreased NK cell activity and IFNγ expression with pSTAT dysregulation in breast cancer patients.
    Konjevic G; Radenkovic S; Srdic T; Jurisic V; Stamatovic Lj; Milovic M
    J BUON; 2011; 16(2):219-26. PubMed ID: 21766489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of anti-TNF therapy on NK cells function and on immunosurveillance against B-cell lymphomas.
    Nocturne G; Boudaoud S; Ly B; Pascaud J; Paoletti A; Mariette X
    J Autoimmun; 2017 Jun; 80():56-64. PubMed ID: 28214146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Constitutive JAK/STAT signaling is the primary mechanism of resistance to JAKi in TYK2-rearranged acute lymphoblastic leukemia.
    Tavakoli Shirazi P; Eadie LN; Page EC; Heatley SL; Bruning JB; White DL
    Cancer Lett; 2021 Aug; 512():28-37. PubMed ID: 33971281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity.
    Miller JS; Tessmer-Tuck J; Pierson BA; Weisdorf D; McGlave P; Blazar BR; Katsanis E; Verfaillie C; Lebkowski J; Radford J; Burns LJ
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):34-44. PubMed ID: 9209739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating the use of JAK inhibitors in inflammatory connective tissue diseases in pediatric patients: an update.
    Chuprin J; McCormack L; Richmond JM; Rashighi M
    Expert Rev Clin Immunol; 2022 Mar; 18(3):263-272. PubMed ID: 35209781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Janus kinase inhibitors alter NK cell phenotypes and inhibit their antitumour capacity.
    Meudec L; Richebé P; Pascaud J; Mariette X; Nocturne G
    Rheumatology (Oxford); 2023 Aug; 62(8):2855-2863. PubMed ID: 36583542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mining for JAK-STAT mutations in cancer.
    Constantinescu SN; Girardot M; Pecquet C
    Trends Biochem Sci; 2008 Mar; 33(3):122-31. PubMed ID: 18291658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. JAK inhibition increases bone mass in steady-state conditions and ameliorates pathological bone loss by stimulating osteoblast function.
    Adam S; Simon N; Steffen U; Andes FT; Scholtysek C; Müller DIH; Weidner D; Andreev D; Kleyer A; Culemann S; Hahn M; Schett G; Krönke G; Frey S; Hueber AJ
    Sci Transl Med; 2020 Feb; 12(530):. PubMed ID: 32051226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perspective: Targeting the JAK/STAT pathway to fight age-related dysfunction.
    Xu M; Tchkonia T; Kirkland JL
    Pharmacol Res; 2016 Sep; 111():152-154. PubMed ID: 27241018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histone deacetylase inhibitors impair NK cell viability and effector functions through inhibition of activation and receptor expression.
    Rossi LE; Avila DE; Spallanzani RG; Ziblat A; Fuertes MB; Lapyckyj L; Croci DO; Rabinovich GA; Domaica CI; Zwirner NW
    J Leukoc Biol; 2012 Feb; 91(2):321-31. PubMed ID: 22124136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.